The spectrum of αβ-TCR amenable targets are traditionally classified into five groups with increasing specificity for tumor cells: (1) ubiquitous antigens (e.g., Her2/neu), (2) overexpressed self-antigens (e.g., Wilms’ Tumor antigen 1, WT1; survivin), (3) differentiation antigens (e.g., tyrosinase), (4) cancer testis antigens (CTAs, e.g., melanoma-associated antigen, MAGE; New York esophageal squamous cell carcinoma-1, NY-ESO-1), and (5) tumor-specific antigens (TSA, e.g., viral-derived oncoproteins, cancer neoantigens) [27,28,29,30]. The gene discussed is ERBB2; the disease is esophagitis.